Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs
1. TAK's FY2024 net profit fell 25.1% year-over-year. 2. Core net profit increased slightly by 2.5% despite currency effects. 3. Revenue rose 7.5% due to favorable forex and strong performance in key areas. 4. Takeda expects limited exposure to U.S. and China tariffs with mitigation strategies. 5. The FY2025 outlook shows stable profits amid investments for future growth.